Novavax Files 8-K Report

TL;DR

Novavax filed an 8-K on Nov 3, 2025, with updates on financials and other events.

AI Summary

On November 3, 2025, Novavax, Inc. filed an 8-K report detailing events that occurred on the same date. The filing indicates updates related to financial statements and exhibits, as well as other events and a Regulation FD disclosure. No specific financial figures or new material agreements were disclosed in the provided excerpt.

Why It Matters

This filing signifies ongoing corporate reporting by Novavax, Inc. to the SEC, providing transparency on recent events and financial information.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not contain information that inherently increases risk.

Key Players & Entities

• Novavax, Inc. (company) — Registrant
• November 3, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• Gaithersburg, Maryland (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.01 — registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Se
• $25 million — transfer authorization has triggered a $25 million milestone payment from Sanofi under the

Filing Documents

• tm2530132d1_8k.htm (8-K) — 33KB
• tm2530132d1_ex99-1.htm (EX-99.1) — 16KB
• tm2530132d1_ex99-1img001.jpg (GRAPHIC) — 2KB
• 0001104659-25-105818.txt ( ) — 221KB
• nvax-20251103.xsd (EX-101.SCH) — 3KB
• nvax-20251103_lab.xml (EX-101.LAB) — 33KB
• nvax-20251103_pre.xml (EX-101.PRE) — 22KB
• tm2530132d1_8k_htm.xml (XML) — 3KB

01. Regulation FD Information

Item 7.01. Regulation FD Information. On November 4, 2025, Novavax, Inc. ("Novavax" or the "Company") issued a press release announcing the information discussed under Item 8.01 hereof. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. Other Events

Item 8.01. Other Events. On November 3, 2025 the Federal Drug Administration approved the transfer application to change the holder of the marketing authorization for Nuvaxovid from Novavax to Sanofi Pasteur Inc. ("Sanofi"). Completion of the transfer authorization has triggered a $25 million milestone payment from Sanofi under the Company's Collaboration and License Agreement with Sanofi. The Company anticipates receipt of payment in the first quarter of 2026. Cautionary Note Regarding Forward-Looking Statements. This Current Report on Form 8-K contains forward-looking covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any statements in the discussion below and elsewhere in this Current Report about expectations, beliefs, plans, objectives, assumptions, or future events or performance of the Company are not historical facts and are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding expected milestone payments under the Sanofi agreement. Generally, forward-looking statements can be identified through the use of words or phrases such as "believe," "may," "could," "will," "would," "possible," "can," "estimate," "continue," "ongoing," "consider," "anticipate," "intend," "seek," "plan," "project," "expect," "should," "would," "aim," or "assume," the negative of these terms, or other comparable terminology, although not all forward-looking statements contain these words.

Forward-looking statements are neither historical

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Novavax's current beliefs and expectations about the future of our business, events and trends, and other future conditions. Forward-looking statements involve estimates, assumptions, risks, and uncertainties that could cause actual results or outcomes to differ materially from those expressed or implied in any forward-looking include, without limitation, challenges or delays related to the requested PMC or in obtaining further regulatory authorization for its COVID-19 vaccine; antigenic drift or shift in the SARS-CoV-2 spike protein, challenges satisfying, alone or together with partners, various safety, efficacy and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; and other risks and uncertainties identified in Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 27, 2025, as updated by the information in Part II, Item 1A "Risk Factors" in our Quarterly Report on Form 10-Q for the qu

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release, Dated November 4, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Novavax, Inc. Date: November 4, 2025 By: /s/ Mark J. Casey Name: Mark J. Casey Title: Executive Vice President, Chief Legal Officer and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR